Lantus (insulin glargine) / Sanofi 
Welcome,         Profile    Billing    Logout  
 89 Diseases   30 Trials   30 Trials   3067 News 


«12...678910111213141516...2829»
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Clinical, Journal:  Computer Vision Syndrome Among Health Sciences Students in Saudi Arabia: Prevalence and Risk Factors. (Pubmed Central) -  Apr 1, 2020   
    The rest of the ergonomic practices were less applied as follows: taking breaks while using the device (66%), sitting with the screen on face level (59%), sitting while the top of the screen on eye level (43%), sitting with the screen more than 50 cm away (32%), using antiglare filter (16%)...However, long duration of device use was not significantly associated with increased CVS symptoms. Ergonomic practices are not usually applied by most of the students, which necessitates more efforts to increase their awareness of the correct way of using devices.
  • ||||||||||  Psychiatric Medication Induced Diabetes Mellitus (ENDOExpo) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_4264;    
    ConclusionPsychiatric medications are important cause of drug induced diabetes and should always be thought as a cause of acute new onset diabetes. Stopping the offending drugs ensues good glycemic control.
  • ||||||||||  metformin / Generic mfg., Lantus (insulin glargine) / Sanofi
    Dka From a Ketogenic Diet and Intermittent Fasting or Ketosis-Prone Diabetes? (ENDOExpo) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_4258;    
    Interestingly, previous metabolic studies show that nutritional ketosis typically generates low levels of serum ketones without a clinically significant anion gap metabolic acidosis. With negative beta cell autoantibodies and preserved beta cell function, this presentation is also consistent with ketosis-prone diabetes type 2B.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, tacrolimus / Generic mfg., Lantus (insulin glargine) / Sanofi
    A Case of Hyperglycemia in Post Pancreas Transplant Patient-Is It Insulin Deficiency or Insulin Resistance (ENDOExpo, Booth 1625) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_3923;    
    His immunosuppressant (IS) medications were tacrolimus, mycophenolate and prednisone...He was started on insulin degludec 24 units daily, which was quickly tapered to 8 units daily due to hypoglycemia...Once the acute stress resolved, his insulin dose needs reduced significantly, tapering down to insulin glargine 5 units daily...This scenario was most consistent with hyperglycemia due to insulin resistance and subsequent relative insulin deficiency during stress, with continued PTx function. This illustrates the importance of detailed assessment and personalized treatment in patients with post-PTx hyperglycemia.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus (ENDOExpo) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_3894;    
    Case Presentation A 77-year-old woman living in a nursing home with a history of T2DM treated with insulin glargine, but for the past three days refused medications with decreased caloric intake...Conclusion Euglycemic DKA is a medical emergency that may be overlooked as patients present without marked hyperglycemia. Physicians should have a high suspicion as this may result in delayed management and potential adverse metabolic consequences.
  • ||||||||||  metformin / Generic mfg., Lantus (insulin glargine) / Sanofi, Januvia (sitagliptin) / Merck (MSD)
    Journal:  Corticotroph adenoma and pituitary fungal infection: a rare association. (Pubmed Central) -  Mar 28, 2020   
    Treatment with systemic anti-fungal drugs is controversial. Endocrine evaluation is recommended at the time of initial presentation of pituitary manifestations.
  • ||||||||||  metformin / Generic mfg., Lantus (insulin glargine) / Sanofi, Januvia (sitagliptin) / Merck (MSD)
    Case report: initial diagnosis of type 1 diabetes / LADA at 93 years (poster area 6) -  Mar 22, 2020 - Abstract #DDG2020DDG_493;    
    This should be borne in mind in slim patients with widely fluctuating glucose levels. A first manifestation of ketoacidosis can occur even in extremely old age (see literature J. Endocrinol Metab 2016, Japanese patient at 96 years).
  • ||||||||||  Soliqua 100/33 (lixisenatide + insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi
    Comparison of iGlarLixi with a basal bolus regimen in patients with type 2 diabetes using propensity score matching (PSM) (poster area 6) -  Mar 22, 2020 - Abstract #DDG2020DDG_367;    
    iGlarLixi as a once-daily fixed combination of insulin glargine 100 U / ml and the GLP-1-RA lixisenatide could be a simple alternative to escalation to a basal bolus (BB) regime. iGlarLixi is an effective alternative to a BB regime with less hypoglycaemia and weight gain for patients with T2D who are not adequately controlled with a BOT at a moderate basal insulin dose.
  • ||||||||||  Soliqua 100/33 (lixisenatide + insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi
    Clinical, Journal:  Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L. (Pubmed Central) -  Mar 14, 2020   
    The difference in β-cell function outcomes in response to medications in youth versus adults supports a more adverse trajectory of β-cell deterioration in youth. iGlarLixi lowered glycated haemoglobin more versus iGlar regardless of T2D duration, with benefit retained even among patients with the longest T2D duration.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Clinical, Journal, HEOR:  Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes. (Pubmed Central) -  Mar 14, 2020   
    iGlarLixi lowered glycated haemoglobin more versus iGlar regardless of T2D duration, with benefit retained even among patients with the longest T2D duration. Insulin degludec is unlikely to be cost-effective compared with insulin glargine for Chinese patients with T2DM whose disease is inadequately controlled with oral antidiabetic drugs.
  • ||||||||||  Soliqua 100/33 (lixisenatide + insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
    Clinical, Clinical data, Journal:  Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes. (Pubmed Central) -  Mar 12, 2020   
    The efficacy of once-daily IGla-U300 in diabetic cats should be further investigated. This analysis demonstrates the clinical benefit of lixisenatide alone or in the formulation of iGlarLixi over the entire dose range of lixisenatide contained in iGlarLixi (5-20µg), supporting the selection of the lixisenatide dose range delivered by the iGlarLixi SoloSTAR pen.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi
    Trial completion, Adverse events, HEOR, Real-world evidence, Real-world:  ATOS: Twelve -Month Study Observing How Insulin-na (clinicaltrials.gov) -  Mar 11, 2020   
    P=N/A,  N=4589, Completed, 
    This analysis demonstrates the clinical benefit of lixisenatide alone or in the formulation of iGlarLixi over the entire dose range of lixisenatide contained in iGlarLixi (5-20µg), supporting the selection of the lixisenatide dose range delivered by the iGlarLixi SoloSTAR pen. Active, not recruiting --> Completed
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Enrollment change:  Comparison Study of Insulin Glargine and NPH Insulin (clinicaltrials.gov) -  Mar 10, 2020   
    P4,  N=0, Withdrawn, 
    This paper summarizes the outcomes of the meeting. N=500 --> 0
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    [VIRTUAL] INSULIN PRICES IN CANADA, SAUDI ARABIA, AND THE US. () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1819;    
    The indexed price for insulin glulisine 100 units/ml vial was 42.2 in Saudi Arabia, 100.0 in Canada, and 548.4 in the US; insulin lispro 100 units/ml pen was 49.6 in Saudi Arabia, 100.0 in Canada, and 697.0 in the US; insulin Glargine 100 units/ml pen was 41.6 in Saudi Arabia, 100.0 in Canada, and 224.8 in the US; insulin detemir 100 units/ml pen was 35.0 in Saudi Arabia, 100.0 in Canada, and 263.5 in the US; Insulin degludec 100 units/ml pen was 63.8 in Saudi Arabia, 100.0 in Canada, and 380.6 in the US; insulin degludec 200 units/ml pen was 64.7 in Saudi Arabia, 100.0 in Canada, and 385.1 in the US. Prices of insulin products on January 1, 2020, were over 4 times higher in the US than in Canada, and over 8 times higher in the US than in Saudi Arabia.
  • ||||||||||  Journal:  Trends in Prices of Popular Brand-Name Prescription Drugs in the United States. (Pubmed Central) -  Mar 3, 2020   
    Changes in prices paid were highly correlated with third-party estimates of changes in drug net prices (ρ = 0.55; P = 3.8 × 10-5), suggesting that the current rebate system, which incentivizes high list prices and greater reliance on rebates, increases overall costs. The growth of drug spending in the United States associated with government-protected market exclusivity is likely to continue; greater price transparency is warranted.
  • ||||||||||  Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi
    New P4 trial:  Effect of Suliqua (EUDRACT) -  Feb 27, 2020   
    P4,  N=50, Ongoing, 
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Preclinical, Journal:  Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. (Pubmed Central) -  Feb 22, 2020   
    NCT04075513. Our results showed that beta cell mass was sustained and hepatic steatosis was prevented, after 8 weeks of treatment with either dapagliflozin or dapagliflozin plus insulin glargine, but not with insulin glargine alone, in db/db mice.
  • ||||||||||  Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk, NN1213 / Novo Nordisk
    Enrollment closed, Trial completion date, Trial primary completion date:  Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes (clinicaltrials.gov) -  Feb 18, 2020   
    P4,  N=250, Active, not recruiting, 
    Our results showed that beta cell mass was sustained and hepatic steatosis was prevented, after 8 weeks of treatment with either dapagliflozin or dapagliflozin plus insulin glargine, but not with insulin glargine alone, in db/db mice. Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Clinical, Journal:  Costs associated with long-acting insulin analogues in patients with diabetes. (Pubmed Central) -  Feb 16, 2020   
    Despite higher drug costs, the real-world overall medical costs of LAIAs are not significantly different from those of NPH in patients with diabetes. The findings may be helpful for formulary decision making for patients with diabetes in a cost-constrained environment.